What Asembia 2026 Confirmed About the Future of Market Access

Las Vegas has a way of concentrating your focus. Three days at Asembia 2026 across sessions, hallway conversations, and the expo floor left us with a clear read on where the market access conversation is landing right now.. 

Here is what stayed with us: 

Access Is No Longer a Support Function 

This came up in some form in nearly every session we attended. The language has shifted from “patient services” and “hub support” to “commercial differentiator” and “access realization” and the shift is far from cosmetic. Manufacturers who continue to treat access as downstream of brand strategy are building on a model that has since evolved.. 

What we kept hearing: having clinical buy-in and formulary coverage is no longer enough to get a therapy to patients. The distance between a prescriber’s intent and a patient receiving treatment  through prior authorization, benefit verification, affordability confusion, and care coordination gaps is where brands are losing ground because access realization transcends mere coverage. Survey data presented during the week put the Day 1 rejection rate for specialty prescriptions at 70 percent. Nearly half of those rejections persisted past 30 days. 

That’s not an access problem at the edges but a structural gap at the center of commercial performance. 

The Policy Environment Is Now an Execution Problem 

There was a time when the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) pricing were discussed on panels on a more theoretical basis. This year, they were operational. The manufacturers are now asking whether their systems, data infrastructure, and contracting teams are built to absorb them. 

The Maximum Fair Prices now published for the first cohort of negotiated drugs landed between 38 and 79 percent below list. Part B drugs enter negotiation for the first time in 2028, with reimbursement calculated from ASP rather than list price, a mechanism more direct than anything the market has dealt with before. And the coverage disruption flowing from the One Big Beautiful Bill Act (OBBBA), Medicaid churn, ACA subsidy expiration, more patients without coverage, is already arriving in hub volumes and patient assistance program demand. 

Price Has Stopped Being the Primary Access Lever 

A survey presented during the week asked pharma executives to identify what drives access for their specialty brands today. Only one in six pointed to price. The majority cited contracting sophistication, utilization management controls, and the ability to demonstrate performance outcomes as the dominant factors. 

This tracks with what we see in the work we do with clients. The access conversation has moved upstream, to formulary design, payer relationship architecture, and field execution, and downstream, to what happens after a prescription is written. Price strategy still matters. But it no longer determines the outcome on its own. 

What determines the outcome is whether manufacturers have built the systems to close the gap between clinical intent and actual therapy initiation and whether they can measure and adjust that gap in real time. 

The Access Realization Gap — and What Closes It 

One of the conversations we were fortunate to have contributed to this year centered on a problem we’ve named the Access Realization Gap: the compounding leakage between clinical buy-in and drug administered to patient. It operates across three layers, perception barriers that prevent prescribers from initiating, process barriers that intercept the prescription once written, and patient barriers that cause drop-off even after successful initiation. Together, they explain why a brand can have strong clinical evidence, solid formulary coverage, and a well-resourced hub and still underperform on access. 

What stood out in our discussions on the floor was how widely this framing resonated. The problem isn’t new. The willingness to name it precisely and to build strategy around closing it,  rather than just optimizing individual touchpoints, felt like a shift in how the industry is thinking. 

Closing the Access Realization Gap is what we mean when we talk about Access Execution: the integrated capability to move access strategy from design to real-world impact across field, data, and patient support functions simultaneously.  Access Execution is proactive, field-led education, pull-through resources built on data that links coverage policy to performance in real time, and tools that give field reimbursement managers and sales reps actionable intelligence rather than lagged reporting. 

Evidence and Integration Are What Win from Here 

The last theme that ran through Asembia across sessions on real-world evidence, contracting, biosimilars, and rare disease was about what separates access programs that hold up over time from those that erode. 

The answer, consistently, was integration. Not more capability, but rather  a connected system. RWE that moves from publication to active deployment in payer negotiations. Contracting that’s built on measurable outcomes.. Field engagement that’s synchronized across brand, account, and patient support teams. Data that flows in one direction across the access journey rather than accumulating in silos. 

The industry has the components. The gap is architecture. 

Asembia 2026 didn’t necessarily reveal new problems. It revealed how seriously the market is finally taking one that has been present for years and how much ground there is still to cover. We left the conference with a sharper sense of where our pharma brands are feeling the most pressure, and what building best-in-class access realization requires. 

If any of this reflects what your team is navigating, we would welcome a conversation. 
 

See AccessSync in action 

Discover how AccessSync customers are turning coverage data into confident HCP conversations — in a 30-minute demo tailored to your brand. Schedule your demo.